Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen

American Journal of Hematology

Volumn 91, Issue 8, 2016, Pages 819-823

  Rytting, Michael E ^a   Jabbour, Elias J ^a   Jorgensen, Jeffrey L ^a   Ravandi, Farhad ^a   Franklin, Anna R ^a   Kadia, Tapan M ^a   Pemmaraju, Naveen ^a   Daver, Naval G ^a   Ferrajoli, Alessandra ^a   Garcia Manero, Guillermo ^a   Konopleva, Marina Y ^a   Borthakur, Gautam ^a   Garris, Rebecca ^a   Wang, Sa ^a   Pierce, Sherry ^a   Schroeder, Kurt ^a   Kornblau, Steven M ^a   Thomas, Deborah A ^a   Cortes, Jorge E ^a   O'Brien, Susan M ^a   Kantarjian, Hagop M ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; OFATUMUMAB; RITUXIMAB; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUGMENTED BERLIN FRANKFURT MUNSTER; BLEEDING; BONE MARROW SUPPRESSION; BONE NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; COMPARATIVE STUDY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; HYPOFIBRINOGENEMIA; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; OUTCOME ASSESSMENT; PANCREATITIS; PRIORITY JOURNAL; THROMBOSIS; TREATMENT OUTCOME;

EID: 84978224232     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24419     Document Type: Article

References (41)

1. Stock W, La M, Bloomfield CD, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? Blood 2008;112:1646.
2. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children of young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003;21:774.
3. Ramanujachar R, Richards S, Hans I, et al. Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer 2007;48:254.
4. Ram R, Wolach O, Vidal L, et al. Addolescents and young adults with acute luymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: Systematic review and meta-analysis. Am J Hematol 2012;87:472–478.
5. Usvasalo A, Raty R, Knuutila S, et al. Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica 93:1161–1168.
6. Ribera J, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk ALL. J Clin Oncol 2008;26:1843.
7. Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative ALL. J Clin Oncol 2009;27:911.
8. Lukenbill J, Advani A. The treatment of adolescents and young adults with acute lymphoblastic leukemia. Curr Hematol Malig Rep 2013;8:91–97.
9. Stock W, Luger S, Advani A, et al. Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of US intergroup trial C10403 [abstract]. Blood (ASH Annual Meeting Abstracts) 2014;124:Abstract 796.
10. Nachman J, La MK, Hunger SP, et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: A report from the Children's Oncology Group. J Clin Oncol 2009;27:5189.
11. Rytting ME, Thomas DA, O'Brien SM, et al. Augmented Berlin–Frankfurt–Munster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer 2014;120:3660–3668.
12. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101:2788–2801.
13. Thomas D, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2014;28:3880–3889.
14. Seibel N, Steinherz PG, Sather SN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 2008;111:2548.
15. Pui C, Howard S. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 2008;9:257–268.
16. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1965;53:457.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163–170.
18. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187.
19. Kurtsberg J, Asselin B, Bernstein M, et al. Ployethylene glycol-conjugated l-asparaginase versus native l-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: A Children's Oncology Group Study (POG 8866). J Pediatr Hematol Oncol 2011;33:610–616.
20. Pullen J, Shuster J, Link M, et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. Leukemia 1999;13:1696–1707.
21. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia. Blood 2010;115:3206.
22. Borowitz M, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group Study. Blood 2008;111:5477.
23. Dworzak MN, Froschl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002;99:1952–1958.
24. Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2002;27:5168–5174.
25. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96:2691–2696.
26. Bassan R, Spinalli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009;113:4153–4162.
27. Ravandi F, Jorgensen J, O'Brien S, et al. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in older adults with acute lymphoblastic leukaemia. Br J Haematol 2016;172:392–400.
28. Gokbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012;120:1868–1876.
29. Ribera JM, Oriol A, Morgades M, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: Final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol 2014;32:1595–1604.
30. Mattano LA, Sather H, Trigg M, et al. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group. J Clin Oncol 2000;18:3262.
31. te Winkel ML, Pieters R, Hop WC, et al. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. J Clin Oncol 2011;29:4143–4150.
32. Nowak-Gottl U, Ahlke I, Fleischhack G, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): Prednisone versus dexamethasone administration. Blood 2003;101:2529–2533.
33. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study. Lancet Oncol 2012;13:403–411.
34. Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013;119:2728–2736.
35. DeAngelo DJ, Stellies M, Martinelli G, et al. Efficacy and safety of inotuzumab ozogamicin (INO) vs. standard of care (SOC) in salvage 1 or 2 patients with acute lymphoblastic leukemia (ALL): An ongoing global phase 3 study. EHA Abstr 2015;103387.
36. Topp MS, Gökbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014;32:4134–4140.
37. Topp MS, Gökbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120:5185–5187.
38. Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. Lancet Oncol 2015;16:57–66. 10.1016/S1470-2045(14)71170-2;.
39. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507–1517.
40. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.
41. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet 2014;385:7–13.